Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-07-21

FDA Approved: UPTRAVI — Supplemental Application (Actelion Pharmaceuticals US, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for UPTRAVI (selexipag) by Actelion Pharmaceuticals US, Inc., updating labeling as part of the supplemental approval…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Uptravi (selexipag)

Snippet

SUPPL AP for UPTRAVI (SELEXIPAG)